Zydus’ anticonvulsant pill gets U.S. FDA nod

Generic drugmaker Zydus has received the final approval from the U.S. FDA to market anticonvulsant drug Vigabatrin Tablets 500 mg. The approved product, whose reference listed drug is Sabril Tablets, will be manufactured at the Group’s formulation manufacturing facility in Ahmedabad, Cadila Healthcare said on Thursday. Vigabatrin decreases the number of seizures in adults and children who have not been able to control their seizures with other treatment, the company said.

Our code of editorial values

This article is closed for comments.
Please Email the Editor

Printable version | May 24, 2022 2:59:12 pm |